Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KRRO
KORRO BIO, INC.
NASDAQ
$12.24
▲ UP 5.34% (0.62)

KEY STATISTICS

Market Cap$121.83 M
52w High$55.89
52w Low$5.20
Dividend Yield—
Frequency—
P/E-1.22
Volume78.43K
Shares Out.9.95M

COMPANY

LEADERSHIP

Ram Aiyar
CHIEF EXECUTIVE
Ram Aiyar

COMPENSATION 2026

Salary$633,200
Stock Awards$0
Incentive Plan Pay$208,956
All Other Comp.$10,500
Total$3,119,591

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 3, 2019
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
57

PRICE TARGET

Target High$23.00
Target Low$15.00
Target Median$22.00
Target Consensus$20.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$187.50K
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2023-11-06Reverse1:50

PRICE

$12.24 ▲ UP 5.34% (+$0.62)
OVERLAYS
$11.50$11.75$12.00$12.259:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM12.24

About Korro Bio, Inc.

https://www.korrobio.com ↗

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

INDUSTRY

Biotechnology

A PRODUCT KORRO BIO, INC. IS KNOWN FOR

KRRO-121
KRRO-121

KRRO-121 is Korro Bio's lead investigational RNA editing therapy for hyperammonemia, advancing after a strategic pivot following KRRO-110's failure, with ongoing development highlighted at January 2026 analyst day.

COMPETITORS

COMPETITOR
ALNY COMPARE
BEAM COMPARE
CRSP COMPARE
NTLA COMPARE
WVE COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
53
LISTED HERE
11
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.6M
IWM
0.00% · 282.6K
LF
LFSC
0.61% · 65.0K
R2US.L
0.00% · 23.8K
AVSC
0.01% · 15.5K
DFAS
0.00% · 10.0K
XRSG.L
0.00% · 9.9K
RSSL
0.00% · 5.3K
OMFS
0.01% · 2.1K
URTY
0.00% · 438
FSEG
0.04% · 209

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
146
TOP 12 OF 146 · RANKED BY POSITION SIZE
Lynx1 Capital Management LP
1.5M sh · $20.27M
Nea Management Company, LLC
1.3M sh · $17.11M
Atlas Venture Life Science Advisors, LLC
1.1M sh · $54.46M
Balyasny Asset Management L.P.
1.0M sh · $11.77M
Vr Adviser, LLC
1.0M sh · $13.31M
Blackrock, Inc.
817.6K sh · $10.78M
Affinity Asset Advisors, LLC
706.9K sh · $8M
Driehaus Capital Management LLC
672.0K sh · $32.18M
Nantahala Capital Management, LLC
660.0K sh · $8.7M
Fmr LLC
563.7K sh · $26.99M
Adage Capital Partners Gp, L.L.C.
541.0K sh · $7.13M
Adar1 Capital Management, LLC
540.1K sh · $7.12M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book3
Overall Score1

INSIDER TRADES

★
DIRECTOR
FORMELA JEAN FRANCOIS
Sale · 249 shares
2026-08-26
★
DIRECTOR
FORMELA JEAN FRANCOIS
Sale · 51 shares
2026-08-26
★
DIRECTOR
FORMELA JEAN FRANCOIS
Sale · 23.6K shares
2026-08-19
★
DIRECTOR
FORMELA JEAN FRANCOIS
Sale · 4.9K shares
2026-08-19

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 3
OVERWEIGHT 2
HOLD 1
SECTOR PERFORM 1
10 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Raymond James OUTPERFORM Cantor Fitzgerald OVERWEIGHT Clear Street BUY William Blair OUTPERFORM Piper Sandler OVERWEIGHT Chardan Capital BUY Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
LBRX$49.54COMPARE
ANRO$35.76COMPARE
ANNX$4.87COMPARE
AURA$7.53COMPARE
SLN$14.63COMPARE
ALT$3.38COMPARE
LRMR$3.85COMPARE
DBVT$13.56COMPARE